Table 3.
|
p Values (partial η2) for main effects |
p Values (partial η2) for interactions |
||||
---|---|---|---|---|---|---|
Outcome measure | Drug treatment (pHBSP or control) | Time of administration (early or delayed) | Day post-injury | Trial each day | Drug × time | Day × trial |
Histology (two-factor ANOVA) | ||||||
Contusion volume | 0.817 (0.06) | 0.252 (0.02) | 0.787 (0.06) | |||
CA1 neuron count | 0.312 (0.02) | 0.768 (0.00) | 0.590 (0.01) | |||
CA3 neuron count | 0.917 (0.00) | 0.558 (0.01) | 0.220 (0.03) | |||
CD68-labeled cell count | 0.040 (0.07) | 0.723 (0.00) | 0.767 (0.00) | |||
Morris water maze (four-factor mixed ANOVA) | ||||||
Time to find platform | 0.022 (0.08) | 0.014 (0.10) | 0.000 (0.75) | 0.000 (0.34) | 0.901 (0.00) | 0.000 (0.16) |
% Time spent in platform quadrant | 0.825 (0.00) | 0.148 (0.03) | 0.000 (0.19) | 0.000 (0.19) | 0.860 (0.00) | 0.000 (0.25) |
Distance traveled to find platform | 0.019 (0.09) | 0.029 (0.08) | 0.000 (0.74) | 0.000 (0.34) | 0.599 (0.01) | 0.000 (0.16) |
Swim speed | 0.448 (0.01) | 0.534 (0.01) | 0.000 (0.11) | 0.028 (0.05) | 0.027 (0.08) | 0.000 (0.17) |
Probe trial: time spent in platform quadrant | 0.416 (0.01) | 0.954 (0.00) | 0.914 (0.00) | |||
Visible platform: time to find platform | 0.263 (0.02) | 0.996 (0.00) | 0.177 (0.03) | |||
Beam walking (three- or four-factor mixed ANOVA) | ||||||
Pre-injury time to cross beam | 0.458 (0.01) | 0.895 (0.00) | 0.000 (0.13) | 0.411 (0.01) | ||
Post-injury time to cross beam | 0.658 (0.00) | 0.294 (0.02) | 0.000 (0.34) | 0.000 (0.14) | 0.366 (0.01) | 0.001 (0.05) |
Beam balance (four-factor mixed ANOVA) | ||||||
Post-injury balance time | 0.815 (0.00) | 0.911(0.00) | 0.000 (0.38) | 0.178 (0.028) | 0.997 (0.00) | 0.012 (0.04) |
pHBSP, pyroglutamate helix B surface peptide; ANOVA, analysis of variance.